Empath Ventures

About The Fund

Empath Ventures is an investment fund that specializes in early-stage startups driving the era of exponential human flourishing, termed Human 3. Their investment focus is on companies that are leading the way in the intersection of life sciences, AI, hardware, software, deep tech, and health tech, often defying traditional categorization and combining these fields in novel ways. With an investment range from $100,000 to $5,000,000 and a sweet spot of around $1,500,000, they target stages including Seed, Series A, and Pre-seed. Empath Ventures identifies itself with the philosophy of Human 3, which is predicated on the belief that humans can achieve much more in terms of health and wellbeing. This philosophy is built on the foundation of scientific rigour established in the era of modern medicine (Human 2) but aims to drastically accelerate human health advancements through exponential technologies and transdisciplinary collaborations. Empath Ventures invests with the vision of not only healing the sick but also preventing illness and enhancing health for the healthy. They have invested in genre-defining companies such as Kerna Labs, Motif Neurotech, Xylo, NeuroBionics, and Superpower at their earliest stages, assisting them with pharma partnerships, talent acquisition, and securing further financing. Their portfolio includes innovative ventures working on next-generation neuromodulation, epigenetic cures for brain cancer, tackling rare neurological disorders, brain longevity, and foundation models for better RNA therapeutics, among others. Based in Los Angeles, Focalpoint is managed by Brom Rector and Sam Tabone. The fund extends an invitation to founders building within the Human 3 space to contact them for potential investment and support.